Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
Trial summary:
CompARE is a phase III randomised trial comparing overall survival time and quality of life from five alternative treatments for high and intermediate risk oropharyngeal cancer. Arms 2. 3 & 4 are closed to recruitment and current randomisation is between Arm 1 (control arm) and Arm 5 (induction durvalumab followed by Arm 1 treatment).
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | | ||
| Planning Benchmark Case | | ||
| Dummy Run | |||
| During Accrual | Individual Case Review | | Prospective outline and planning reviews for at least first case. Benchmark and prospective outlining for implementation of 5+5 technique. |
| Data collection | | All patients | |
| Dosimetry | | ||
| QA Streamlining | | De-ESCALaTE, NIMRAD, DARS and PATHOS |
RTTQA contact: compareqa.enh-tr@nhs.net
Chief investigator: Prof Hisham Mehanna (University of Birmingham)
RT Lead: Dr Andrew Hartley (University Hospitals Birmingham)
Sponsor: University of Birmingham (compare@trials.bham.ac.uk)
Funder: Clinical Trials Awards and Advisory Committee (CTAAC) and AstraZeneca